Product Description
Anacetrapib is a potent inhibitor of CETP that increases circulating levels of high-density lipoprotein (HDL) cholesterol and lowers the levels of non-HDL cholesterol [particularly low-density lipoprotein (LDL) cholesterol]. (Sourced from: https://doi.org/10.1093/eurheartj/ehab863)
Mechanisms of Action: CETP Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Merck
Company Location: KENILWORTH NJ 07033
Company CEO: Robert M. Davis
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Hypercholesterolemia|Dyslipidemia|Coronary Artery Disease|Coronary Disease|Hyperlipoproteinemia Type II|Hyperlipoproteinemias|Hyperlipidemia|Myocardial Ischemia|Myocardial Infarction|Atherosclerosis
Phase 2: Hypercholesterolemia|Hyperlipoproteinemia Type V|Hyperlipidemia|Dyslipidemia
Phase 1: Dyslipidemia|Kidney Diseases|Hepatic Insufficiency|Liver Failure|Hypercholesterolemia|Hyperlipidemia|Hyperlipoproteinemias|Other
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| Study of Anaceptrapib in Heterozygous Familial Hypercholesterolemia | P3 |
Completed |
Hypercholesterolemia |
2018-11-13 |
|
| REVEAL-Vasc | N/A |
Completed |
Atherosclerosis |
2018-05-01 |
|
| REVEAL | P3 |
Active, not recruiting |
Atherosclerosis |
2017-01-31 |
|
| REVEAL Version 1.0 | P3 |
Unknown status |
Coronary Disease|Myocardial Infarction |
2016-09-25 |